Surgical Technique and Efficacy Analysis of Extra-pseudocapsular Transnasal Transsphenoidal Surgery for Pituitary Microprolactinoma

• Published in: Current medical science 2022-12, Vol.42 (6), p.1140-1147
• Main Authors: Wan, Xue-yan, Li, Lin-han, Chen, Juan, Wang, Jun-wen, Liu, Yan-chao, Huang, Yi-min, Shu, Kai, Buchfelder, Michael, Fahlbusch, Rudolf, Lei, Ting
• Format: Article
• Language: English
• Subjects: Adenoma - pathology; Adenoma - surgery; Female; Humans; Medicine; Medicine & Public Health; Pituitary Gland - diagnostic imaging; Pituitary Gland - pathology; Pituitary Gland - surgery; Pituitary Neoplasms - diagnostic imaging; Pituitary Neoplasms - drug therapy; Pituitary Neoplasms - surgery; Prolactinoma - diagnostic imaging; Prolactinoma - drug therapy; Prolactinoma - surgery; Retrospective Studies
• ISSN: 2096-5230; 2523-899X
• DOI: 10.1007/s11596-022-2678-1

Objective To elucidate the role of transsphenoidal surgery in the treatment of pituitary microprolactinoma. Methods The clinical data of 107 prolactinoma cases treated by extra-pseudocapsular transnasal transsphenoidal surgery (ETTS) for different indications in our department since 2011 was retrospectively analyzed. Results The most common indication was the ineffectiveness of oral medication (41.1%), followed by the personal willingness of the patient (35.5%), and 20.6% of the patients were young women with clear tumor boundaries. The pseudocapsule was not observed in 63 cases (58.9%), incomplete pseudocapsule was observed in 26 cases (24.3%), and complete pseudocapsule in 18 cases (16.8%). A total of 97 patients (90.7%) obtained 1-year post-operation remission. According to the relative location of the adenoma and pituitary gland on the MRI scan, 46 patients were classified into a central type, 59 a lateral type, and 2 a supra-pituitary type. Two patients developed hypogonadism, one patient developed hypocortisolism, and one patient developed post-operative hypothyroidism. Two patients were administrated with hormone replacement treatment, and the treatment was stopped within one week. There was no permanent hypopituitarism. Further investigation demonstrated that the adenoma types could affect the remission rates of hyperprolactinemia and gross total resection rate in microprolactinoma. Conclusion ETTS was an effective treatment for pituitary microprolactinomas. This could be the first choice for patients who presented enclosed adenoma on the MRI and were potentially curable in a preoperative evaluation. Maximal safe removal of the adenoma by ETTS with the aim to increase the sensitivity of the drugs was also recommended for patients with invasive dopamine agonist resistant prolactinomas and patients with difficulty in childbirth.